Renaissance Period – Darkholme Keep http://darkholmekeep.net/ Wed, 18 May 2022 17:12:42 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://darkholmekeep.net/wp-content/uploads/2021/06/icon-7-70x70.png Renaissance Period – Darkholme Keep http://darkholmekeep.net/ 32 32 Credit Suisse Group analysts give JPMorgan Chase & Co. (NYSE:JPM) a price target of $160.00 https://darkholmekeep.net/credit-suisse-group-analysts-give-jpmorgan-chase-co-nysejpm-a-price-target-of-160-00/ Wed, 18 May 2022 17:12:42 +0000 https://darkholmekeep.net/credit-suisse-group-analysts-give-jpmorgan-chase-co-nysejpm-a-price-target-of-160-00/ JPMorgan Chase & Co. (NYSE: JPM) was assigned a price target of $160.00 by Credit Suisse Group research analysts in a report on Wednesday, Borsen Zeitung reports. Credit Suisse Group’s price target indicates a potential upside of 32.01% from the company’s previous close. Several other equity analysts have also recently released reports on JPM. Zacks […]]]>

JPMorgan Chase & Co. (NYSE: JPM) was assigned a price target of $160.00 by Credit Suisse Group research analysts in a report on Wednesday, Borsen Zeitung reports. Credit Suisse Group’s price target indicates a potential upside of 32.01% from the company’s previous close.

Several other equity analysts have also recently released reports on JPM. Zacks Investment Research upgraded shares of JPMorgan Chase & Co. from a “sell” rating to a “hold” rating and set a target price of $147.00 for the company in a Monday, March 21 research note. Citigroup lowered its price target on JPMorgan Chase & Co. shares from $188.00 to $175.00 and set a “neutral” rating for the company in a Tuesday, Jan. 18 research note. Oppenheimer upgraded JPMorgan Chase & Co. shares from a “market performer” rating to an “outperformer” rating and set a price target of $167.00 for the company in a Tuesday 3 may. Argus cut its price target on JPMorgan Chase & Co. shares from $177.00 to $155.00 in a Thursday, April 14 report. Finally, UBS Group set a price target of $197.00 on JPMorgan Chase & Co. shares in a Wednesday, March 2 report. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned the company’s stock a buy rating. Based on MarketBeat data, JPMorgan Chase & Co. currently has an average rating of “Hold” and a consensus target price of $161.67.

Shares of JPM traded down $0.98 during trading hours on Wednesday, hitting $121.20. The stock recorded a trading volume of 450,814 shares, compared to an average volume of 14,959,824 shares. The company has a debt ratio of 1.16, a quick ratio of 0.82 and a current ratio of 0.82. The company has a 50-day moving average price of $130.15 and a 200-day moving average price of $147.31. JPMorgan Chase & Co. has a fifty-two week low of $115.37 and a fifty-two week high of $172.96. The company has a market capitalization of $355.97 billion, a price/earnings ratio of 8.99, a PEG ratio of 2.14 and a beta of 1.12.

JPMorgan Chase & Co. (NYSE:JPM – Get Rating) last reported results on Wednesday, April 13. The financial services provider reported earnings per share (EPS) of $2.63 for the quarter, missing the consensus estimate of $2.73 per ($0.10). JPMorgan Chase & Co. posted a net margin of 33.61% and a return on equity of 16.58%. The company posted revenue of $30.72 billion in the quarter, versus analyst estimates of $30.53 billion. In the same quarter of the previous year, the company had earned earnings per share of $4.50. The company’s revenue for the quarter was down 4.8% year over year. As a group, analysts predict JPMorgan Chase & Co. will post EPS of 11.13 for the current fiscal year.

In other news, insider Ashley Bacon sold 21,012 shares of the company in a trade on Tuesday, April 19. The stock was sold at an average price of $130.04, for a total transaction of $2,732,400.48. Following the completion of the transaction, the insider now directly owns 178,588 shares of the company, valued at $23,223,583.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. Additionally, CEO Jennifer Piepszak sold 4,668 shares of the company in a trade on Thursday, April 14. The stock was sold at an average price of $126.19, for a total value of $589,054.92. As a result of the transaction, the CEO now owns 11,135 shares of the company, valued at $1,405,125.65. The disclosure of this sale can be found here. Insiders of the company hold 0.79% of the shares of the company.

A number of large investors have recently increased or reduced their stake in JPM. Norges Bank bought a new position in JPMorgan Chase & Co. in the fourth quarter worth $4,092,843,000. Vanguard Group Inc. increased its stake in JPMorgan Chase & Co. by 2.6% in the first quarter. Vanguard Group Inc. now owns 266,854,574 shares of the financial services provider valued at $36,377,615,000 after purchasing an additional 6,792,220 shares during the period. GQG Partners LLC increased its stake in JPMorgan Chase & Co. by 403.3% in the fourth quarter. GQG Partners LLC now owns 5,095,612 shares of the financial services provider valued at $806,728,000 after purchasing an additional 4,083,231 shares during the period. Renaissance Technologies LLC increased its stake in JPMorgan Chase & Co. by 1,543.7% in the fourth quarter. Renaissance Technologies LLC now owns 3,341,486 shares of the financial services provider valued at $529,124,000 after purchasing an additional 3,138,200 shares during the period. Finally, Capital World Investors increased its stake in JPMorgan Chase & Co. by 3.9% in the third quarter. Capital World Investors now owns 74,302,154 shares of the financial services provider valued at $12,162,752,000 after purchasing an additional 2,764,341 shares during the period. Hedge funds and other institutional investors hold 70.35% of the company’s shares.

About JPMorgan Chase & Co. (Get an evaluation)

JPMorgan Chase & Co operates as a worldwide financial services company. It operates through four segments: Consumer & Community Banking (CCB), Corporate & Investment Bank (CIB), Commercial Banking (CB) and Asset & Wealth Management (AWM). The CCB segment offers s deposit, investment and lending products, payments and consumer services; lending, deposit, cash management and payment solutions for small businesses; mortgage origination and management activities; residential mortgages and home equity loans; and credit card, car loan and leasing services.

Featured Articles

Analyst Recommendations for JPMorgan Chase & Co. (NYSE: JPM)



Get news and reviews for JPMorgan Chase & Co. Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for JPMorgan Chase & Co. and related companies with MarketBeat.com’s free daily email newsletter.

]]>
$1.12 EPS expected for Focus Financial Partners Inc. (NASDAQ:FOCS) this quarter https://darkholmekeep.net/1-12-eps-expected-for-focus-financial-partners-inc-nasdaqfocs-this-quarter/ Mon, 16 May 2022 08:20:51 +0000 https://darkholmekeep.net/1-12-eps-expected-for-focus-financial-partners-inc-nasdaqfocs-this-quarter/ Wall Street brokers expect Focus Financial Partners Inc. (NASDAQ:FOCS – Get Rating) to report earnings per share of $1.12 for the current quarter, according to Zacks Investment Research. Four analysts have made earnings estimates for Focus Financial Partners. The highest EPS estimate is $1.13 and the lowest is $1.10. Focus Financial Partners posted earnings per […]]]>

Wall Street brokers expect Focus Financial Partners Inc. (NASDAQ:FOCS – Get Rating) to report earnings per share of $1.12 for the current quarter, according to Zacks Investment Research. Four analysts have made earnings estimates for Focus Financial Partners. The highest EPS estimate is $1.13 and the lowest is $1.10. Focus Financial Partners posted earnings per share of $0.98 in the same quarter last year, which would indicate a positive growth rate of 14.3% year over year. The company is due to release its next quarterly earnings report on Monday, January 1.

According to Zacks, analysts expect Focus Financial Partners to report annual earnings of $4.59 per share for the current fiscal year, with EPS estimates ranging from $4.52 to $4.72. For the next fiscal year, analysts expect the company to post earnings of $5.21 per share, with EPS estimates ranging from $4.90 to $5.43. Zacks’ EPS calculations are an average based on a survey of research firms that track Focus Financial Partners.

Focus Financial Partners (NASDAQ:FOCS – Get Rating) last released quarterly earnings data on Thursday, May 5. The company reported earnings per share (EPS) of $1.16 for the quarter, beating analyst consensus estimates of $1.09 by $0.07. Focus Financial Partners achieved a return on equity of 25.03% and a net margin of 2.02%. The company posted revenue of $536.57 million in the quarter, compared to $515.65 million expected by analysts. During the same period of the previous year, the company achieved EPS of $0.83. The company’s revenue for the quarter increased by 36.1% compared to the same quarter last year.

(A d)

What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%!

When you start getting paid 26% on your money, your financial troubles tend to evaporate.

A number of research companies have recently published reports on FOCS. Truist Financial cut its price target on Focus Financial Partners from $78.00 to $65.00 in a Friday, May 6 report. Goldman Sachs Group cut its price target on Focus Financial Partners from $75.00 to $65.00 and set a “buy” rating for the company in a Thursday, March 31 report. Raymond James lowered his price target on Focus Financial Partners from $66.00 to $60.00 and set an “outperform” rating for the company in a Tuesday, April 5 report. Finally, Zacks Investment Research upgraded Focus Financial Partners from a “sell” rating to a “hold” rating in a report released on Friday. One equity research analyst gave the stock a hold rating and six gave the company’s stock a buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $69.71.

A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its stake in Focus Financial Partners by 10.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,043 shares of the company worth $231,000 after purchasing an additional 475 shares during the period. Renaissance Technologies LLC increased its stake in Focus Financial Partners by 1.8% in the 1st quarter. Renaissance Technologies LLC now owns 121,300 shares of the company worth $5,548,000 after purchasing an additional 2,100 shares during the period. Northern Trust Corp increased its stake in Focus Financial Partners by 4.2% in the first quarter. Northern Trust Corp now owns 784,273 shares of the company worth $35,872,000 after purchasing an additional 31,336 shares during the period. Verition Fund Management LLC purchased a new stake in Focus Financial Partners in Q1 worth approximately $3,578,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Focus Financial Partners by 14.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 437,570 shares of the company worth $20,015,000 after purchasing an additional 56,857 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s shares.

FOCS opened at $36.22 on Monday. The stock has a 50-day moving average price of $42.60 and a 200-day moving average price of $52.62. Focus Financial Partners has a 12-month low of $33.20 and a 12-month high of $69.13. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt ratio of 2.06. The stock has a market capitalization of $2.79 billion, a P/E ratio of 59.38, a PEG ratio of 0.51 and a beta of 1.25.

Focus Financial Partners Company Profile (Get a rating)

Focus Financial Partners Inc provides wealth management services primarily to ultra-high and high net worth individuals, families and businesses. Its wealth management services include investment advice, financial and tax planning, counseling, tax return preparation, family office services and other services.

Further reading

Get a Free Copy of Zacks Research Report on Focus Financial Partners (FOCS)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Focus Financial Partners right now?

Before you consider Focus Financial Partners, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Focus Financial Partners was not on the list.

Although Focus Financial Partners currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

]]>
TSR, Inc. (NASDAQ:TSRI) Short Interest Down 35.4% in April https://darkholmekeep.net/tsr-inc-nasdaqtsri-short-interest-down-35-4-in-april/ Sat, 14 May 2022 09:54:18 +0000 https://darkholmekeep.net/tsr-inc-nasdaqtsri-short-interest-down-35-4-in-april/ TSR, Inc. (NASDAQ:TSRI – Get Rating) experienced a significant drop in short-term interest during the month of April. As of April 30, there was short interest totaling 8,200 shares, down 35.4% from the April 15 total of 12,700 shares. Based on an average trading volume of 31,400 shares, the day-to-cover ratio is currently 0.3 days. […]]]>

TSR, Inc. (NASDAQ:TSRI – Get Rating) experienced a significant drop in short-term interest during the month of April. As of April 30, there was short interest totaling 8,200 shares, down 35.4% from the April 15 total of 12,700 shares. Based on an average trading volume of 31,400 shares, the day-to-cover ratio is currently 0.3 days. Currently, 0.7% of the company’s shares are sold short.

NASDAQ:TSRI shares opened at $7.67 on Friday. The company has a market capitalization of $16.46 million, a PE ratio of 2.35 and a beta of 0.86. The company has a 50-day moving average of $9.17 and a 200-day moving average of $9.67. The TSR has a 12-month low of $7.10 and a 12-month high of $16.80.

Major investors have recently changed their positions in the company. Renaissance Technologies LLC increased its position in TSR shares by 29.8% in the first quarter. Renaissance Technologies LLC now owns 99,850 shares of the technology company worth $936,000 after purchasing an additional 22,900 shares during the period. Vanguard Group Inc. increased its position in TSR shares by 215.3% in the first quarter. Vanguard Group Inc. now owns 74,007 shares of the technology company worth $693,000 after purchasing an additional 50,537 shares during the period. Dimensional Fund Advisors LP increased its position in TSR shares by 8.7% in the first quarter. Dimensional Fund Advisors LP now owns 61,748 shares of the technology company worth $571,000 after buying 4,949 additional shares during the period. Finally, Acadian Asset Management LLC increased its position in TSR shares by 304.3% in the first quarter. Acadian Asset Management LLC now owns 9,840 shares of the technology company worth $92,000 after purchasing an additional 7,406 shares during the period. Institutional investors hold 7.50% of the company’s shares.

About RST (Get an evaluation)

TSR, Inc, a staffing firm, focuses on recruiting information technology (IT) professionals for short and long term assignments, permanent placements, projects and provides contract computer programming services to its customers in the New York, New England metropolitan area. , and the Mid-Atlantic region.

Further reading



Get news and reviews for TSR Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for TSR and related companies with MarketBeat.com’s free daily email newsletter.

]]>
Short-Term Interest in Agile Therapeutics, Inc. (NASDAQ:AGRX) Drops 88.5% https://darkholmekeep.net/short-term-interest-in-agile-therapeutics-inc-nasdaqagrx-drops-88-5/ Wed, 11 May 2022 18:17:45 +0000 https://darkholmekeep.net/short-term-interest-in-agile-therapeutics-inc-nasdaqagrx-drops-88-5/ Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) was the target of a sharp drop in short-term interest during the month of April. As of April 30, there was short interest totaling 286,900 shares, down 88.5% from the April 15 total of 2,500,000 shares. Based on an average daily trading volume of 312,300 shares, the short […]]]>

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) was the target of a sharp drop in short-term interest during the month of April. As of April 30, there was short interest totaling 286,900 shares, down 88.5% from the April 15 total of 2,500,000 shares. Based on an average daily trading volume of 312,300 shares, the short interest ratio is currently 0.9 days.

A number of large investors have recently bought and sold shares of the company. First Citizens Bank & Trust Co. bought a new position in shares of Agile Therapeutics during the first quarter for a value of approximately $42,000. Renaissance Technologies LLC increased its stake in Agile Therapeutics by 341.6% during the fourth quarter. Renaissance Technologies LLC now owns 162,900 shares of the specialty pharmaceutical company worth $80,000 after acquiring an additional 126,015 shares during the period. Virtu Financial LLC increased its stake in Agile Therapeutics by 771.4% during the fourth quarter. Virtu Financial LLC now owns 237,642 shares of the specialty pharmaceutical company worth $116,000 after acquiring an additional 210,370 shares during the period. GSA Capital Partners LLP increased its stake in Agile Therapeutics by 25.1% during the fourth quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company worth $358,000 after acquiring an additional 147,194 shares during the period. Finally, BlackRock Inc. increased its stake in Agile Therapeutics by 2.5% during the fourth quarter. BlackRock Inc. now owns 1,507,654 shares of the specialty pharmaceutical company worth $736,000 after acquiring 37,394 additional shares during the period. 27.96% of the shares are held by institutional investors.

AGRX has been the subject of a number of research analyst reports. Maxim Group downgraded Agile Therapeutics from a “buy” rating to a “hold” rating in a Friday, April 8 report. Zacks Investment Research upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a Tuesday, May 3, research report. Finally, StockNews.com launched coverage on Agile Therapeutics stocks in a research report on Thursday, May 5. They set a “sell” rating for the company. One equity research analyst rated the stock with a sell rating, two issued a hold rating and two assigned the company a buy rating. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $100.40.

Agile Therapeutics stock traded down $0.14 during Wednesday’s trading, hitting $1.65. 320 shares of the company were traded, against an average volume of 239,174. The company’s 50-day moving average is $9.80 and its two-hundred-day moving average is $16.78. Agile Therapeutics has a 52-week minimum of $1.64 and a 52-week maximum of $69.60. The company has a market capitalization of $6.05 million, a price-earnings ratio of -0.06 and a beta of 1.57.

Agile Therapeutics (NASDAQ:AGRX – Get Rating) last reported quarterly results on Wednesday, March 30. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing analyst consensus estimates of ($6.80) by ($1.20). Agile Therapeutics recorded a negative return on equity of 376.29% and a negative net margin of 1,825.82%. The company posted revenue of $1.51 million for the quarter, versus $1.58 million for analysts. During the same period last year, the company posted ($8.00) earnings per share. As a group, research analysts expect Agile Therapeutics to post an EPS of -14.8 for the current fiscal year.

About Agile Therapeutics (Get a rating)

Agile Therapeutics, Inc, a women’s healthcare company, researches, develops and markets prescription contraceptive products for women in the United States. Its flagship product is Twirla, also known as AG200-15, a once-weekly prescription combined hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four withdrawal bleeding episodes per year; AG200-15 smaller patch (SmP), which is a treatment regimen designed to provide shorter, lighter withdrawal bleeding and improved contraceptive efficacy; AG200-15 ER SmP, a regimen that allows a woman to extend her contraceptive cycle length, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who cannot or do not want to take estrogen.

Read more



Get news and reviews for Agile Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Agile Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.

]]>
A Montreal choreographer takes a sci-fi approach in Ballet BC’s What If https://darkholmekeep.net/a-montreal-choreographer-takes-a-sci-fi-approach-in-ballet-bcs-what-if/ Mon, 09 May 2022 18:06:20 +0000 https://darkholmekeep.net/a-montreal-choreographer-takes-a-sci-fi-approach-in-ballet-bcs-what-if/ Links to the breadcrumb local arts Entertainment The idea of ​​creating life artificially or synthetically appeals to Dorotea Saykaly Publication date : May 09, 2022 • 22 minutes ago • 3 minute read • Join the conversation Ballet BC presents its final program of the season May 12-14 at the Queen Elizabeth Theatre. Pictured is […]]]>

The idea of ​​creating life artificially or synthetically appeals to Dorotea Saykaly

Content of the article

Ballet BC: What if

Advertisement 2

Content of the article

When: May 12-14 at 8 p.m.

Or: Queen Elizabeth Theatre, 630 Hamilton Street, Vancouver

Tickets: $21.75-$115.25

Ballet BC’s third and final program of the season features three world premieres of new talent from the company: German choreographer Felix Landerer contributes with Everything will be OK; Vancouver’s Out Innerspace piece is called Strange Attractor; and Montreal choreographer Dorotea Saykaly presents Relic.

We spoke to Saykaly about her piece, described as a “look at creation through a scientific lens,” and which won the inaugural Emily Molnar Emerging Choreographer Award.

Q: What is your previous experience with Ballet BC?

A: In 2005, I did an intensive eight-month internship at Arts Umbrella. As part of the program, I took a course with the company. I’ve followed them since Emily Molnar took over in 2009. And with the Emerging Choreographer Award, I got to know the company well because the project got behind schedule. It was extended, which was wonderful enough to get to know the dancers and the company better.

Advertisement 3

Content of the article

Q: How did you become the recipient of the award?

A: There was a call in 2019. You write a letter of intent and propose an idea that you would like to develop. It’s mostly written but you should provide excerpts from your past work that best represent your vision and style. And with the award comes the opportunity to choreograph with the company.

Q: How does this new work, Relic, fit in with your previous pieces?

A: It’s definitely an evolution of the last two years. More than that, probably. There was a focus on a type of physicality, on a kind of theme. There is a theme that has interested me for a while. It is the idea of ​​creating life artificially or synthetically. I’m a big science fiction fan. The main question is often: what makes us human beings? It was a big driver for me.

Advertisement 4

Content of the article

We apologize, but this video failed to load.

Q: How do you translate science fiction ideas into physical terms?

A: I always start from a physical point of view. I try to understand what a body is trying to understand about itself, about its environment. In this way I try to codify the movement with the dancers. Visually, there are tools that I use to help me, whether it’s with the set design or the lighting. I also work with voice over. I like text, and I like when choreographers bring text to a creation. I worked on writing the voiceover and recorded it. I try to keep it minimal so the focus is on the dancers.

Q: Are you a science fiction reader or viewer?

A: I haven’t read a lot of science fiction. My favorite writing is Mary Shelley’s Frankenstein, which some would say is the beginning of science fiction. Visually, I grew up with Blade Runner in the house. It’s my mother’s favorite movie. I had this visual stimulus from an early age. And then it varies. Essays, podcasts. A press article could be a source of inspiration. I like to call my approach science fiction renaissance. I am interested in classical art forms with Renaissance statues and paintings. There are so many riches that we can draw from it.

Q: How much do you explain to dancers? Do you give them a lot of background?

A: When we started last year, I provided the dancers with a playlist and a list of movies and videos that inspired the piece. Some dancers love doing this research, some don’t. This year, although the team is still very present and the references are still very much in my mind, I immersed myself more in the action in the studio. So maybe there’s less outside inspiration. But I like to let them participate in the process. The more you know, the deeper you can dig. And you can choose what you decide to use for studio work.

Advertisement 1

comments

Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. See our Community Guidelines for more information and details on how to adjust your email settings.

]]>
Berry (NASDAQ:BRY) Announces Earnings, Beats Estimates of $0.10 per EPS https://darkholmekeep.net/berry-nasdaqbry-announces-earnings-beats-estimates-of-0-10-per-eps/ Sat, 07 May 2022 16:37:13 +0000 https://darkholmekeep.net/berry-nasdaqbry-announces-earnings-beats-estimates-of-0-10-per-eps/ Berry (NASDAQ:BRY – Get Rating) announced its quarterly earnings data on Wednesday. The energy company reported earnings per share of $0.51 for the quarter, beating consensus analyst estimates of $0.41 by $0.10, MarketWatch Earnings reports. Berry had a negative net margin of 9.37% and a positive return on equity of 8.51%. In the same quarter […]]]>

Berry (NASDAQ:BRY – Get Rating) announced its quarterly earnings data on Wednesday. The energy company reported earnings per share of $0.51 for the quarter, beating consensus analyst estimates of $0.41 by $0.10, MarketWatch Earnings reports. Berry had a negative net margin of 9.37% and a positive return on equity of 8.51%. In the same quarter last year, the company posted earnings per share of $0.07.

BRY stock traded at $0.32 during Friday’s trading, hitting $10.99. The company had a trading volume of 374,856 shares, compared to an average volume of 410,136. The company has a 50-day simple moving average of $10.90 and a 200-day simple moving average of $9.67. The company has a market capitalization of $887.55 million, a price-earnings ratio of -17.17 and a beta of 2.34. The company has a debt ratio of 0.57, a quick ratio of 0.79 and a current ratio of 0.79. Berry has a 12-month low of $4.72 and a 12-month high of $12.85.

The company also recently announced a dividend, which will be paid on Wednesday, June 15. Investors of record on Monday, May 16 will receive a dividend of $0.13. The ex-dividend date is Friday, May 13. Berry’s dividend payout ratio (DPR) is currently -37.50%.

Hedge funds and other institutional investors have recently changed their positions in the company. Goldman Sachs Group Inc. increased its stake in Berry by 12.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 83,539 shares of the energy company valued at $704,000 after acquiring an additional 9,090 shares during the period. Barclays PLC increased its stake in Berry shares by 165.1% in Q4. Barclays PLC now owns 81,860 shares of the energy company valued at $690,000 after buying an additional 50,986 shares during the period. Credit Suisse AG acquired a new position in shares of Berry in Q4 worth $664,000. Sei Investments Co. increased its stake in Berry shares by 31.3% in Q4. Sei Investments Co. now owns 58,300 shares of the energy company valued at $491,000 after purchasing an additional 13,900 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Berry stock in Q4 worth $420,000. Institutional investors and hedge funds hold 92.68% of the company’s shares.

BRY has been the subject of a number of research analyst reports. Wells Fargo & Company raised its price target on Berry shares from $10.00 to $12.00 and gave the company an “underweight” rating in a Monday, March 14 report. Zacks Investment Research upgraded Berry’s shares from a “strong sell” rating to a “hold” rating in a Monday, April 11 research report. KeyCorp raised its price target on Berry shares from $12.00 to $13.00 and gave the stock an “overweight” rating in a Thursday, April 14 research report. Finally, Piper Sandler upgraded Berry shares from a “neutral” rating to an “overweight” rating and raised her price target for the stock from $11.00 to $14.00 in a research report Thursday, April 7. One financial analyst has assigned the stock a sell rating, two have issued a hold rating and three have assigned the stock a buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $12.13.

About Berry (Get a rating)

Berry Petroleum Company, LLC, formerly Berry Petroleum Company, is an independent energy company. The Company is engaged in the production, development, exploitation and acquisition of petroleum and natural gas. The Company’s principal reserves and producing properties are located in California (South Midway-Sunset (SMWSS)-Steam Floods, North Midway-Sunset (NMWSS)-Diatomite, NMWSS-New Steam Floods, Texas (Permian and E.

Further reading

Earnings History for Berry (NASDAQ:BRY)



Get news and reviews for Berry Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Berry and related companies with MarketBeat.com’s free daily email newsletter.

]]>
Kopin (NASDAQ:KOPN) upgraded at Zacks Investment Research https://darkholmekeep.net/kopin-nasdaqkopn-upgraded-at-zacks-investment-research/ Thu, 05 May 2022 05:44:09 +0000 https://darkholmekeep.net/kopin-nasdaqkopn-upgraded-at-zacks-investment-research/ Kopin (NASDAQ:KOPN – Get a Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released Thursday, Zacks.com reports. According to Zacks, “Kopin Corporation is a leading developer and provider of innovative wearable technologies and solutions for integration into head-worn computing and display systems for military, industrial […]]]>

Kopin (NASDAQ:KOPN – Get a Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released Thursday, Zacks.com reports.

According to Zacks, “Kopin Corporation is a leading developer and provider of innovative wearable technologies and solutions for integration into head-worn computing and display systems for military, industrial and consumer customers. Kopin’s technologies and solutions are available as components providing individual capabilities or as reference systems providing integrated solutions. Kopin has a long history of developing technologies required for wearable computer headsets for the military, consumers, or industry. Kopin helped develop head-mounted displays for the F-35 Joint Strike Fighter, created the Golden-i, a wearable helmet reference design for the industry, and collaborated on numerous wearable products with a range of companies including Vuzix, Motorola Solutions and Reconnaissance Instruments. Kopin developed and commercialized breakthrough technologies such as the heterojunction bipolar transistors (HBTs) that power billions of cell phones and the microdisplays that brought vivid images. “

Separately, StockNews.com began covering Kopin in a report on Thursday, March 31. They put a “sell” mark on the stock.

KOPN opened at $1.78 on Thursday. The stock has a 50-day moving average price of $2.26 and a 200-day moving average price of $3.57. The company has a market capitalization of $163.57 million, a PE ratio of -11.87 and a beta of 2.25. Kopin has a 1-year low of $1.52 and a 1-year high of $10.13.

Kopin (NASDAQ:KOPN – Get Rating) last released its quarterly results on Tuesday, March 8. The company reported ($0.04) earnings per share (EPS) for the quarter. The company posted revenue of $13.20 million for the quarter, versus a consensus estimate of $11.50 million. Kopin had a negative net margin of 30.07% and a negative return on equity of 25.73%. In the same quarter of the previous year, the company had earned earnings per share of $0.02. As a group, equity analysts expect Kopin to post -0.15 EPS for the current fiscal year.

Institutional investors and hedge funds have recently been buying and selling shares of the company. Two Sigma Investments LP increased its position in Kopin shares by 9,403.9% during the third quarter. Two Sigma Investments LP now owns 1,302,546 shares of the company valued at $6,682,000 after purchasing an additional 1,316,546 shares last quarter. Two Sigma Advisers LP increased its stake in Kopin by 1,164.5% during the third quarter. Two Sigma Advisers LP now owns 904,113 shares of the company valued at $4,638,000 after acquiring an additional 832,613 shares during the period. State Street Corp increased its stake in Kopin by 12.2% in the fourth quarter. State Street Corp now owns 7,560,334 shares of the company valued at $30,922,000 after acquiring an additional 821,491 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Kopin by 55.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,216,848 shares of the company valued at $5,257,000 after acquiring an additional 434,948 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Kopin shares by 336.8% in the 4th quarter. Renaissance Technologies LLC now owns 222,764 shares of the company valued at $911,000 after purchasing an additional 171,764 shares during the period. Hedge funds and other institutional investors hold 35.78% of the company’s shares.

About Kopine (Get a rating)

Kopin Corporation, together with its subsidiaries, invents, develops, manufactures and sells microdisplays, subassemblies, wearable and head-mounted systems and related components for defense, enterprise, industrial and consumer products in the United States, Asia-Pacific, Europe and internationally.

Featured articles

Get a Free Copy of Zacks’ Research Report on Kopin (KOPN)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for Kopin Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Kopin and related companies with MarketBeat.com’s FREE daily newsletter.

]]>
The inside story of Nottingham Forest’s remarkable renaissance https://darkholmekeep.net/the-inside-story-of-nottingham-forests-remarkable-renaissance/ Tue, 03 May 2022 06:00:00 +0000 https://darkholmekeep.net/the-inside-story-of-nottingham-forests-remarkable-renaissance/ Cooper’s philosophy is to play forward and backward with speed, crossing the lines. The focus is always on how Forest can dominate the ball and score goals: Leicester’s 4-1 thrashing in the FA Cup was Cooper’s vision in full HD format. Against his former club Swansea on Saturday, Cooper’s side had just 30 per cent […]]]>

Cooper’s philosophy is to play forward and backward with speed, crossing the lines. The focus is always on how Forest can dominate the ball and score goals: Leicester’s 4-1 thrashing in the FA Cup was Cooper’s vision in full HD format.

Against his former club Swansea on Saturday, Cooper’s side had just 30 per cent possession but still missed out on 5-1 wins, proof that it’s not the amount of the ball that matters to him, but what his team does.

Cooper can be flexible – one of his most satisfying moments this season was a tactical adjustment against rivals Derby, when he switched from a back three to a back four in the first half – and is also happy to accept feedback from its players. He prefers a non-hierarchical approach, where experienced squad members are encouraged to speak up.

Forest captain Lewis Grabban and Steve Cook have been invaluable this season, although some fans may be surprised that Gaëtan Bong – who hasn’t played this year – is also an influential figure.

While Hughton was determined to time well, Cooper prefers to trust his players. Anyone who is late is then considered letting the group down, which, for Cooper, is a more serious punishment than a fine.

Cooper also takes a personal touch when signing players: He convinced Cook and Keinan Davis to sign in January by holding lengthy Zoom chats, outlining his philosophy and telling them where they would fit into his team. Another side of Cooper that exemplifies his personal touch is the way he has rounded up office staff, frequently visiting them after training to make it clear that the club has an ‘just as one’ mentality.

Backroom staff and attention to detail are key to success

He will point to his behind-the-scenes staff as crucial figures in the turnaround. First-team coaches Alan Tate and Steven Reid are highly experienced, with long playing careers, while head of analysis Steve Rands worked under Pep Guardiola and Frank Lampard. Former England and Everton sports science manager David Tivey has meanwhile helped make Forest one of the most in-form sides in the division.

“There’s a lot of meeting and attention to detail,” Cook said. “Everything is explained how we play in a certain way and if we lose games we know exactly why.

“The training is very tactical, with a good variety of drills, and everyone is fully prepared for the matches.”

The training ground is vitally important to Cooper. Very early in his tenure, a new £20,000 auditorium was created, where team and individual meetings are held.

Substantial investment has also gone into pitch improvements, cameras and analysis software, with director of football Kyriakos Dourekas and head of football operations Ed Henderson overseeing the restructuring.

It is these small adjustments that usher Forest into a new era and meet the demands of a big club.

Evangelos Marinakis, the club’s owner, is fully on board and speaks regularly with Cooper. Managing Director Dane Murphy was appointed last summer and was recently named CEO of the Year by FC Business magazine.

Marinikas’ January backing is seen as key, with the signings of Cook, Davis and £2m striker Sam Surridge proving a masterstroke, and it can be revealed Forest have also been making serious attempts to sign Spartak Moscow’s Victor Moses in March.

Moïse was available after special dispensation was granted by Fifa and UEFA following the Russian invasion of Ukraine, but the talks broke down.

Now the focus is on Bournemouth with the match postponed to February, an intriguing subplot.

Forest were frustrated when Bournemouth called off the game less than four hours before kick-off due to high winds, even filing a complaint with the Football League.

Automatic promotion is now in play, with Forest determined to continue their upward streak. As Brian Clough once said, “I hope no one is stupid enough to write us off.”

]]>
Atento SA (NYSE:ATTO) Brief Interest Update https://darkholmekeep.net/atento-sa-nyseatto-brief-interest-update/ Sat, 30 Apr 2022 22:03:49 +0000 https://darkholmekeep.net/atento-sa-nyseatto-brief-interest-update/ Atento SA (NYSE:ATTO – Get Rating) was the target of a sharp rise in short interest in April. As of April 15, there were short interests totaling 11,000 shares, an increase of 54.9% from the March 31 total of 7,100 shares. Based on an average daily volume of 24,300 shares, the day-to-cover ratio is currently […]]]>

Atento SA (NYSE:ATTO – Get Rating) was the target of a sharp rise in short interest in April. As of April 15, there were short interests totaling 11,000 shares, an increase of 54.9% from the March 31 total of 7,100 shares. Based on an average daily volume of 24,300 shares, the day-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Several large investors have recently increased or reduced their stake in the company. JPMorgan Chase & Co. increased its position in Atento by 40,368.8% during the 4th quarter. JPMorgan Chase & Co. now owns 6,475 shares of the business services provider valued at $165,000 after purchasing an additional 6,459 shares during the period. Diametric Capital LP acquired a new stake in Atento during Q4 worth approximately $202,000. Intrepid Capital Management Inc. bought a new stake in Atento stock in Q4 valued at $481,000. Renaissance Technologies LLC increased its stake in Atento shares by 19.6% in the third quarter. Renaissance Technologies LLC now owns 47,523 shares of the business services provider valued at $1,341,000 after acquiring an additional 7,780 shares in the last quarter. Finally, Morgan Stanley increased its stake in Atento by 1.0% in the second quarter. Morgan Stanley now owns 122,228 shares of the business services provider worth $3,134,000 after buying an additional 1,224 shares last quarter.

NYSE ATTO shares were up $0.50 at midday Friday, hitting $25.45. 9,427 shares of the stock trade in hands, compared to its average volume of 21,178. The company has a quick ratio of 1.37, a current ratio of 1.24 and a leverage ratio of 19 ,16. Atento has a one-year minimum of $18.75 and a one-year maximum of $32.00. The company’s 50-day moving average is $26.62 and its 200-day moving average is $25.57.

Atento (NYSE:ATTO – Get Rating) last released its quarterly results on Wednesday, March 30. The business services provider reported ($2.43) earnings per share (EPS) for the quarter. The company posted revenue of $327.20 million in the quarter, versus a consensus estimate of $352.00 million. Atento had a negative return on equity of 129.55% and a negative net margin of 6.23%. As a group, stock analysts predict Atento will post EPS of 0.55 for the current fiscal year.

A number of brokerages have published reports on ATTO. Barrington Research reissued an “outperform” rating on Atento shares in a research report on Friday, April 1. StockNews.com began covering Atento shares in a research note on Thursday, March 31. They set a “buy” rating on the stock. Finally, Zacks Investment Research upgraded Atento shares from a “hold” rating to a “strong sell” rating in a Wednesday, April 6 research note. One financial analyst has assigned the stock a sell rating, one has issued a hold rating and two have assigned the stock a buy rating. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $29.33.

Atento Company Profile (Get a rating)

Atento SA, together with its subsidiaries, provides customer relationship management and business process outsourcing services and solutions in Brazil, America, Europe, Middle East and Africa. It offers a range of front-end and back-end services, including sales, customer service, technical support, collections and back office, as well as claims processing and credit management.

Read more



Get news and reviews for Atento Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Atento and related companies with MarketBeat.com’s free daily email newsletter.

]]>
LeMaitre Vascular (NASDAQ:LMAT) High to “Buy” Zacks Investment Research https://darkholmekeep.net/lemaitre-vascular-nasdaqlmat-high-to-buy-zacks-investment-research/ Thu, 28 Apr 2022 05:35:36 +0000 https://darkholmekeep.net/lemaitre-vascular-nasdaqlmat-high-to-buy-zacks-investment-research/ LeMaitre Vascular (NASDAQ:LMAT – Get a Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released Thursday, Zacks.com reports. The company currently has a price target of $50.00 on the medical device supplier’s inventory. Zacks Investment Research’s target price indicates a potential upside of 12.38% from […]]]>

LeMaitre Vascular (NASDAQ:LMAT – Get a Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released Thursday, Zacks.com reports. The company currently has a price target of $50.00 on the medical device supplier’s inventory. Zacks Investment Research’s target price indicates a potential upside of 12.38% from the company’s current price.

According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects people worldwide. LeMaitre develops, manufactures and markets vascular devices disposable and implantable to meet the needs of vascular surgeons and interventionalists.LeMaitre’s diverse product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and is supported by an organization growing, specialized, and highly trained vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists to improve procedural efficiency and minimize patient recovery time.”

Several other equity research analysts also weighed in on LMAT. StockNews.com picked up coverage from LeMaitre Vascular in a Thursday, March 31 report. They issued a “hold” rating for the company. Barrington Research reduced its target price on LeMaitre Vascular from $62.00 to $54.00 in a Friday, February 25 report. Two equity research analysts gave the stock a hold rating and four gave the stock a buy rating. According to MarketBeat, the stock currently has an average buy rating and an average target price of $59.40.

(A d)

Inflation, gas prices, and now this? Retirees are now at risk of outliving their money unless they make this change to their retirement savings IMMEDIATELY. Take action to protect your retirement savings before Biden strikes again.

Shares of LeMaitre Vascular opened at $44.49 on Thursday. The company has a market capitalization of $976.64 million, a price/earnings ratio of 35.31, a P/E/G ratio of 3.39 and a beta of 1.32. LeMaitre Vascular has a 52-week minimum of $39.48 and a 52-week maximum of $64.50. The stock has a 50-day simple moving average of $45.64 and a 200-day simple moving average of $47.58.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its results on Thursday, February 24. The medical device supplier reported earnings per share of $0.28 for the quarter, missing Thomson Reuters’ consensus estimate of $0.31 per ($0.03). LeMaitre Vascular had a return on equity of 12.42% and a net margin of 17.42%. The company posted revenue of $39.50 million in the quarter, versus analyst estimates of $39.70 million. In the same quarter last year, the company posted earnings per share of $0.34. The company’s revenue for the quarter increased by 5.2% compared to the same quarter last year. On average, equity research analysts expect LeMaitre Vascular to post EPS of 1.39 for the current year.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 7,929 shares of LeMaitre Vascular in a trade that took place on Wednesday, March 2. The stock was sold at an average price of $48.22, for a total value of $382,336.38. The sale was disclosed in a filing with the SEC, which is available via this link. Insiders hold 16.50% of the shares of the company.

A number of hedge funds and other institutional investors have recently changed their LMAT holdings. BlackRock Inc. increased its position in LeMaitre Vascular by 5.9% in Q3. BlackRock Inc. now owns 3,115,834 shares of the medical device supplier worth $165,420,000 after purchasing an additional 173,671 shares during the period. Copeland Capital Management LLC increased its position in LeMaitre Vascular shares by 7.1% during the fourth quarter. Copeland Capital Management LLC now owns 1,205,199 shares of the medical device supplier valued at $60,537,000 after purchasing an additional 80,112 shares during the period. Summit Creek Advisors LLC increased its position in shares of LeMaitre Vascular by 21.0% during the fourth quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical device supplier valued at $18,151,000 after purchasing an additional 62,754 shares during the period. Renaissance Technologies LLC increased its position in shares of LeMaitre Vascular by 123.8% during the third quarter. Renaissance Technologies LLC now owns 103,500 shares of the medical device supplier worth $5,495,000 after purchasing an additional 57,261 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of LeMaitre Vascular by 26.3% during the fourth quarter. ProShare Advisors LLC now owns 207,271 shares of the medical device supplier valued at $10,412,000 after purchasing an additional 43,213 shares during the period. 85.82% of the shares are currently held by institutional investors.

LeMaitre Vascular Society Profile (Get a rating)

LeMaitre Vascular, Inc designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers an angioscope, a fiber optic catheter used to view the lumen of a blood vessel; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily block blood flow; infusion catheters for infusing blood and other fluids into the vascular system; and thrombectomy catheters, which feature a silicone balloon to remove thrombus in the venous system.

Further reading

Get a Free Copy of Zacks’ LeMaitre Vascular (LMAT) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in LeMaitre Vascular right now?

Before you consider LeMaitre Vascular, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and LeMaitre Vascular wasn’t on the list.

While LeMaitre Vascular currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

]]>